Sigachi Industries Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/u340k9qjhzmv4cz34y3w0bh3.pdf

Key Takeaways


The Hyderabad Fire: Damage, Costs & Recovery

O.S. Reddy: "Yes, exactly this is consequent to the fire accident that carrying in third quarter also because all Hyderabad unit overheads were spread across the other units. That is one thing. And also the material transportation cost from Hyderabad unit, there is a lot of raw material was available and this has been moved to the Dahej and Jhagadia units."

Demand & Pricing: Constrained, Not Broken

O.S. Reddy: "Not at all. Pricing also it is increasing and then demand is there and only this is because of the production constraints."

Dahej Expansion: The Capacity Bridge

Amit Raj Sinha: "Hyderabad facility was housing a 6,000 metric tons per annum facility of MCC. Current expansion at Dahej SEZ is building up a 12,000 metric tons per annum facility. So that's nearly double the capacity. So I would say that at this moment our focus is not really to ramp up the Hyderabad facility because there are legal angles to it."

Cystic Fibrosis API: A New Growth Vector

O.S. Reddy: "Yes, that is after 12 months. Yes, after 12 months there is because that is in R&D that product has been — that is development took place and then that is post development then there is a possibility to get this revenue INR250 crores after 12 months."

Insurance & Regulatory Milestones

O.S. Reddy: "Next week we are submitting those documents and before 31st March we are expecting some ad hoc amount and post 31st March the final claim may be received."

Guidance & Commitments

CommitmentSpecificsTimeline
Dahej MCC capacity commissioning12,000 metric tons per annum facilityQ3 FY27
Dahej CCS facility commissioning1,800 tons disintegrant facilityQ3 FY27
Production normalizationProduction picks up from Q4, gradually improvingQ4 FY26 into Q1/Q2 FY27
FY27–28 guidance maintainedFY27 and FY28 as earlier; transition-period slowdown in existing units but full-year capacities come in during FY27FY27 partial, FY28 full normalcy
Margin recoveryDouble-digit EBITDA expected; FY28 onwards would be good, FY27 partially a momentumFY27 partial, FY28 full
Cystic Fibrosis API revenueINR250 crores possible after 12 months post-commercialization~12 months from commercialization
Insurance ad hoc paymentSome ad hoc amount expectedBefore March 31, 2026
Promoter shareholding increasePromoters intend to increase shareholdingIn a few quarters, not this quarter

Key Metrics

MetricQ3 FY26
Total operating income₹117.2 cr
EBITDA₹5.7 cr, margin of 4.6%
Net loss₹0.02 cr, PAT margin of (0.01%)
MCC segment revenue₹61.72 cr
O&M segment revenue₹13.35 cr
API segment revenue₹14.13 cr
Gross margin changeReduced by 6–7% YoY, driven by raw material cost increase
MCC segment gross margin~40%
O&M segment gross margin~22%
API segment gross margin~10%
Cellulose-based excipient capacity18,000 MTPA (Dahej 9,882 MTPA, Jhagadia 8,118 MTPA)
Capacity utilization70% to 73%
Exports share of production~62%
MCC volumes (9M FY26)~10,000 MT against 9M capacity of ~13,500 MT
Promoter pledge₹3.77 cr shares, less than 10% of total share capital, ~26% of promoter holding
Insurance claim expected~₹70 cr total (fixed assets ₹48 cr, inventory ₹4 cr, BI loss ₹25 cr); ad hoc ₹20–25 cr expected
Cystic Fibrosis API revenue guidance₹250 cr, expected after 12 months from commercialization
Long-term debtNil, only working capital debt outstanding